93 239

Cited 2 times in

Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.

Authors
Chung, HY; Koo, J; Kwon, SK; Kang, MI; Moon, SH; Park, JY; Shin, CS; Yoon, BK; Yoon, HK; Chang, JS; Chung, YS; Park, HM
Citation
Clinical interventions in aging, 8:597-603, 2013
Journal Title
Clinical interventions in aging
ISSN
1176-90921178-1998
Abstract
PURPOSE: This study investigated the efficacy and safety of monthly risedronate, with and without cholecalciferol, on 25-hydroxyvitamin D (25[OH]D) levels and bone markers in Korean patients with osteoporosis.



METHODS: A randomized, double-blinded, prospective, 16-week clinical trial was conducted in ten hospitals. A total of 150 subjects with osteoporosis were randomized to one of the two treatment groups: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74) or RSDM (monthly risedronate 150 mg alone, n = 76). We measured serum levels of 25-hydroxyvitamin D (25[OH]D), parathyroid hormone (PTH), and bone markers, as well as performing muscle-function tests at baseline and after 16 weeks of treatment.



RESULTS: After 16 weeks, serum 25(OH)D levels significantly increased from 17.8 to 26.8 ng/mL in the RSDM+ group, but did not change in the RSDM group. The RSDM+ group exhibited significantly decreased serum PTH from 46 to 36.7 pg/mL, while the RSDM group showed a tendency for PTH to increase from 38 to 40.6 pg/mL. In both groups, serum bone-specific alkaline phosphatase and C-terminal telopeptide rapidly declined, with significance at 16 weeks; there were no significant differences between the groups.



CONCLUSION: A once-monthly pill of risedronate and cholecalciferol provided equivalent antiresorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D levels over the 16-week treatment period without significant adverse events in Korean patients with osteoporosis.
MeSH terms
Absorptiometry, PhotonAgedAlkaline Phosphatase/bloodBone Density Conservation Agents/*therapeutic useChi-Square DistributionCholecalciferol/*administration & dosageCollagen Type I/bloodDouble-Blind MethodDrug CombinationsEtidronic Acid/administration & dosage/*analogs & derivativesFemaleHumansMiddle AgedOsteoporosis, Postmenopausal/blood/*drug therapyPeptides/bloodProspective StudiesRepublic of KoreaTreatment OutcomeVitamin D/*analogs & derivatives/blood
DOI
10.2147/CIA.S44395
PMID
23761968
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
AJOU Authors
정, 윤석
Full Text Link
Files in This Item:
597-603.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse